Skip to main content
. 2023 Jan 20;11(2):277. doi: 10.3390/microorganisms11020277

Figure 2.

Figure 2

Clinical response to a 4-week supplementation with the multistrain probiotic in the per-protocol population. (A) Decrease in mean weekly abdominal pain score between V1 and V2. Paired t-test; *: p < 0.05; (B) decrease in mean number of days per week with diarrhoea (score of 6 or 7 on the Bristol Stool Scale) between V1 and V2; (C) increase in mean global Gastrointestinal Quality of Life Index (GIQLI) score between V1 and V2; Wilcoxon test, ***: p < 0.001; ****: p < 0.0001.